Research summary, original research, 2014

Three-Dimensional Fusion Computed Tomography Decreases Radiation Exposure, Procedure Time, And Contrast Use During Fenestrated Endovascular Aortic Repair

McNally MM, Scali ST, Feezor RJ, Neal D, Huber TS, Beck AW. Journal of vascular surgery. 2014

Read the original paper

In plain language

At one US centre, 3D fusion computed tomography (CT) overlay during fenestrated aortic repair was linked to roughly halved patient radiation dose, shorter fluoroscopy time and less contrast. Staff dose was not measured, so any benefit to the fluoroscopy team is inferred.

At a glance

Type of study
Original research, Retrospective cohort study
Who was studied
Patients, Vascular surgeons
Size
n = 72 patients
Where
United States
Summary based on
the full text

What it found

  • Overall patient radiation dose was lower with 3D fusion CT than without.

    Key figures: 5000±280 vs 2200±1300 mGy*cm2; P<.0001

  • Fluoroscopy time was lower overall with 3D fusion CT.

    Key figures: 84±36 vs 55±21 minutes; P=.0004

  • In three- and four-vessel fenestrated endovascular aneurysm repair (FEVAR), radiation dose and procedure time both fell with 3D fusion CT.

    Key figures: 5400 ± 2225 vs 2700 ± 1400 mGy; P < .0001; procedure time 330 ± 100 vs 230 ± 50 minutes; P = .002

  • Contrast use fell substantially overall.

    Key figures: 86±25 vs 34±15 mL; P<.0001

  • Staff dose was not measured because of inconsistent badge use; reduced staff exposure was only assumed.

Limits to keep in mind

This was a single-surgeon, single-institution before-after comparison that also changed imaging systems, with possible learning-curve effects and a lower body mass index (BMI) in the 3D CT group. No staff dosimetry was collected.

How this summary was made

ORSIF prepared this summary with AI assistance from the full text of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.